ITEM METADATA RECORD
Title: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
Authors: Wensing, Annemarie M J ×
van de Vijver, David A
Angarano, Gioacchino
Asjö, Birgitta
Balotta, Claudia
Boeri, Enzo
Camacho, Ricardo
Chaix, Maire-Laure
Costagliola, Dominique
De Luca, Andrea
Derdelinckx, Inge
Grossman, Zehava
Hamouda, Osamah
Hatzakis, Angelos
Hemmer, Robert
Hoepelman, Andy
Horban, Andrzej
Korn, Klaus
Kücherer, Claudia
Leitner, Thomas
Loveday, Clive
MacRae, Eilidh
Maljkovic, Irina
de Mendoza, Carmen
Meyer, Laurence
Nielsen, Claus
Op de Coul, Eline L
Ormaasen, Vidar
Paraskevis, Dimitris
Perrin, Luc
Puchhammer-Stöckl, Elisabeth
Ruiz, Lidia
Salminen, Mika
Schmit, Jean-Claude
Schneider, Francois
Schuurman, Rob
Soriano, Vincent
Stanczak, Grzegorz
Stanojevic, Maja
Vandamme, Anne-Mieke
Van Laethem, Kristel
Violin, Michela
Wilbe, Karin
Yerly, Sabine
Zazzi, Maurizio
Boucher, Charles A #
Issue Date: Sep-2005
Publisher: Published by the University of Chicago Press for the Infectious Diseases Society of America
Series Title: The Journal of Infectious Diseases vol:192 issue:6 pages:958-966
Abstract: BACKGROUND: Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis. METHODS: We determined the baseline rate of drug resistance in 2208 therapy-naive patients recently and chronically infected with HIV-1 from 19 European countries during 1996-2002. RESULTS: In Europe, 1 of 10 antiretroviral-naive patients carried viruses with > or = 1 drug-resistance mutation. Recently infected patients harbored resistant variants more often than did chronically infected patients (13.5% vs. 8.7%; P=.006). Non-B viruses (30%) less frequently carried resistance mutations than did subtype B viruses (4.8% vs. 12.9%; P<.01). Baseline resistance increased over time in newly diagnosed cases of non-B infection: from 2.0% (1/49) in 1996-1998 to 8.2% (16/194) in 2000-2001. CONCLUSIONS: Drug-resistant variants are frequently present in both recently and chronically infected therapy-naive patients. Drug-resistant variants are most commonly seen in patients infected with subtype B virus, probably because of longer exposure of these viruses to drugs. However, an increase in baseline resistance in non-B viruses is observed. These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated.
URI: 
ISSN: 0022-1899
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Clinical and Epidemiological Virology (Rega Institute)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy

 




All items in Lirias are protected by copyright, with all rights reserved.

© Web of science